Acadia Pharma (ACAD) Tops Q1 EPS by 5c, Misses on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 20.57 +0.10 (0.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.47 | 52 Week High | $42.49 | |||
| Open | $20.47 | 52 Week Low | $16.64 | |||
| Day High | $20.82 | P/E | N/A | |||
| Day Low | $20.45 | EPS | $-0.42 | |||
| Volume | 1,708,950 | |||||
